Escitalopram
Prescription medicine for depression and anxiety disorders that stops nerve cells from taking serotonin back up.

Related comparisons
Escitalopram vs FluoxetineDETAILED OVERVIEW
What is Escitalopram?
Escitalopram is a prescription antidepressant, a medicine for depression. It is also used for anxiety disorders, such as generalized anxiety and panic disorder. It is the active form of a drug called citalopram, and is sold as Cipralex and Lexapro, among others.
It stops nerve cells from taking serotonin back up, and the full effect takes weeks to develop. A large comparison study ranked it near the top for both effectiveness and tolerability. The official prescribing information warns that in patients under 25, especially at the start of treatment, the risk of suicidal thoughts and behavior rises. Together with other drugs that act on serotonin it can cause life-threatening serotonin syndrome, and it must not be combined with MAO inhibitors. It can also cause heart rhythm problems. About 10–20% of users notice lower sex drive, delayed orgasm or erection problems, and these can be lasting. Stopping it suddenly can cause withdrawal symptoms.
ATC code
N06AB10
Prescription
Prescription only (Rx)
Mechanism
Selective serotonin reuptake inhibitor; acts on the serotonin transporter
Half-life
27-32 h (once-daily dosing)
Onset
2-6 weeks (full antidepressant response)
Community accounts note Escitalopram as having one of the cleanest tolerability and side-effect profiles among SSRIs, supported by the Cipriani 2018 meta-analysis ranking it in the top tier for efficacy. Users describe a quiet subjective profile – lowering anxiety and supporting mood without strong stimulant or sedating character. Full therapeutic benefit typically emerges over 4-8 weeks, so patience is essential during initiation. Sexual dysfunction (delayed orgasm, reduced libido) is commonly reported, consistent with the SSRI class. The 27-32-hour half-life provides stable plasma levels with once-daily dosing. Caution: discontinuation syndrome on abrupt cessation – taper under clinical guidance. QT-prolongation risk at higher doses warrants ECG monitoring.
⚠ Not clinical evidence – based on user accounts.
Data console
Lab data
Cipriani A, Furukawa TA, Salanti G et al. . Comparative efficacy of 21 antidepressants for MDD. Lancet. 2018;391(10128):1357-1366..
Mnie-Filali O, El Mansari M, Scarna H, Haddjeri N . [Escitalopram: a selective inhibitor and allosteric modulator of the serotonin transporter].. Encephale.
Aronson S, Delgado P . Escitalopram.. Drugs Today (Barc).
Safety
Side effects, stop signs, contraindications
Side effects · 8
- Increased risk of suicidal thoughts and behavior in patients under 25, especially at treatment start and dose changes (FDA boxed warning); close monitoring required.
- Serotonin syndrome (agitation, hyperthermia, myoclonus, tachycardia, diarrhea), especially combined with other serotonergic drugs; can be life-threatening.
- Discontinuation syndrome on abrupt stopping: dizziness, headache, irritability, 'electric shock' sensations, sleep disturbance; requires slow tapering.
- Sexual dysfunction (reduced libido, delayed orgasm, erectile dysfunction) common (about 10–20%) and may persist.
- Gastrointestinal effects: nausea (10–15%), diarrhea, dry mouth, decreased appetite; usually in the first weeks.
- Dose-dependent QT prolongation (> 20 mg/day not recommended) with risk of torsades de pointes; insomnia, headache, sweating also common.
- Hyponatremia / SIADH, especially in the elderly and with diuretics; fatigue, confusion, seizures may be warning signs.
- Increased bleeding risk (with NSAIDs, aspirin, anticoagulants) and induction of mania/hypomania in those with bipolar predisposition.
Contraindications · 3
- MAOi within 14 days (serotonin syndrome)
- Concurrent pimozide (QT prolongation)
- Congenital long-QT syndrome
Related Pharmaceuticals
Same therapeutic category
Studies
Related research and clinical findings
Comparative efficacy of 21 antidepressants for MDD
Cipriani A, Furukawa TA, Salanti G et al.
[Escitalopram: a selective inhibitor and allosteric modulator of the serotonin transporter].
Mnie-Filali O, El Mansari M, Scarna H, Haddjeri N
Escitalopram.
Aronson S, Delgado P
Telegram
Have a question about Escitalopram?
Educational drug info from official sources (PubMed, FDA, EMA). Does NOT replace medical consultation or the SmPC. Talk to your doctor!
Personalized consultation
Want a detailed conversation tailored to your data?
Fill out the prep intake form (your goals, training and health data), and the advisor prepares from it to give genuinely personalized guidance.
Fill out the form~5–7 min · prep questionnaire · confidential · GDPR-compliant
The information here is for educational and scientific purposes only. Medication use requires medical consultation and a prescription. The indications, dose ranges, and side effects listed here do NOT replace the official Summary of Product Characteristics (SmPC) or consultation with a physician. Do not start or stop any medication on your own. In an emergency, call your local emergency number.